Related Experiment Video
Updated: Aug 20, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast
Hong-My Nguyen1, Wyatt Paulishak1, Mariam Oladejo1
1Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Abilene, TX, 79601, USA.
Abstract:
Heterogeneity of the tumor microenvironment (TME) and the lack of a definite targetable receptor in triple-negative breast cancer (TNBC) has carved a niche for this cancer as a particularly therapeutically challenging form of breast cancer. However, recent advances in high-throughput genomic analysis have provided new insights into the unique microenvironment and defining characteristics of various subsets of TNBC. This improved understanding has contributed to the development of novel therapeutic strategies including targeted therapies such as PARP inhibitors and CDK inhibitors. Moreover, the recent FDA approval of the immune checkpoint inhibitor against programmed cell death protein 1 (PD-1), pembrolizumab and atezolizumab, holds the promise of improving the quality of life and increasing the overall survival of TNBC patients. This recent approval is one of the many therapeutically novel strategies that are currently being exploited in clinical trials toward eventual contribution to the oncologist's toolbox against TNBC. In this review, we comprehensively discuss TNBC's distinct TME and its immunophenotype. Furthermore, we highlight the histological and molecular classification of this cancer. More importantly, we describe how these characteristics and classifications contribute to the current standards of care and how they steer the development of newer and more targeted therapies toward achieving peak therapeutic goals in the treatment of TNBC.
Insights
Triple-negative breast cancer (TNBC) is challenging due to its heterogeneous tumor microenvironment (TME). Advances in genomics reveal TNBC subsets, guiding new targeted therapies and immunotherapies like PD-1 inhibitors for improved patient outcomes.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to tumor microenvironment (TME) heterogeneity and lack of specific targetable receptors.
- Recent high-throughput genomic analyses offer new insights into TNBC's unique microenvironment and molecular subsets.
Purpose of the Study:
- To comprehensively review the distinct TME and immunophenotype of TNBC.
- To highlight the histological and molecular classification of TNBC.
- To describe how these classifications inform current standards of care and drive the development of novel targeted therapies.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of genomic, histological, and immunophenotypic characteristics of TNBC.
- Discussion of emerging therapeutic strategies and their clinical implications.
Main Results:
- Genomic insights have identified distinct TNBC subsets with unique microenvironmental features.
- Novel therapeutic strategies, including PARP inhibitors, CDK inhibitors, and PD-1 immune checkpoint inhibitors (pembrolizumab, atezolizumab), are emerging.
- FDA approvals of PD-1 inhibitors offer promise for improved survival and quality of life in TNBC patients.
Conclusions:
- Understanding TNBC's heterogeneity and immunophenotype is crucial for developing effective treatments.
- Targeted therapies and immunotherapies represent promising avenues for improving TNBC management.
- Continued research into TNBC classification and TME characteristics will refine therapeutic strategies and enhance patient outcomes.
